CJC-1295 DAC

The original development study identified an albumin-binding, modified GHRH analog as CJC-1295. The FDA’s December 2024 evaluation distinguishes non-DAC CJC-1295 free base/acetate from DAC-related substances and describes inconsistent naming. It found no data to assess the non-DAC forms’ safety and effectiveness; clinical references concerned DAC-related material with salt forms not specified. A product name alone cannot establish molecular identity.

The DAC design includes a reactive chemical group that enables albumin binding and prolonged exposure. In the human pulsatility study, healthy men had higher trough and mean GH one week after injection, while pulse frequency and magnitude were unchanged. Sustained exposure does not mean GH pulses disappear, and retained pulses do not establish long-term safety.

The trials establish sustained hormonal activity that merits further study. They do not establish a standard amount of muscle gain, fat loss, better sleep, improved skin, bone-density benefit or longer life. The FDA evaluation found insufficient effectiveness evidence for subcutaneous CJC-1295-related substances to treat growth hormone deficiency. A higher GH or IGF-I result is not itself proof of clinical benefit.

The human trials used single and repeated weight-based subcutaneous doses, with weekly or biweekly study schedules. They do not validate a universal 100-microgram, 0.3–0.5 mg or 2–3 mg regimen, an intramuscular substitute, a bodybuilding cycle, or a dose for a product labeled without DAC. Product identity, route, concentration and indication must be established separately. Neither these studies nor the FDA assessment supplies a universal reconstitution volume, refrigerated shelf life, home-injection plan or protective cycling calendar.

The short trial abstract reported no serious adverse reactions. The FDA safety record separately identifies serious events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions, along with immunogenicity and peptide-quality concerns. Those findings must be considered together; a short favorable trial summary does not establish safety for years of use. Exact risks depend on the studied material, route and population.

The FDA evaluation describes an unpublished HIV-lipodystrophy trial stopped after a participant’s death, drawing on anecdotal reports; it does not establish that CJC-1295 caused the death. Long-term human safety remains unknown. The compounding evaluation and withdrawn-nomination listing are not approval of a finished medicine or a universal legal determination about a particular prescription.

An acute study in 18 healthy men found synergistic GH release with GHRH plus GHRP-6. It did not use CJC-1295 or ipamorelin. Complementary receptor pathways give a reason to study combinations; they do not establish superior muscle gain, fat loss or safety from CJC-1295/ipamorelin, sermorelin combinations or broader recovery stacks. No protective receptor-reset schedule is established by the sources reviewed here.

Editorial source check: October 26, 2026. Original development and human trial publications were checked through indexed abstracts. The CJC-specific portions of the FDA December 2024 evaluation and the current FDA safety record were read. Journal full texts were not reviewed. This is an editorial source revision, not clinician signoff or approval of every related guide, comparison, tool or product. This site retains both CJC-1295 and CJC-1295 DAC routes as related references, not two proven interchangeable treatments.